Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat Maintenance in High-Risk Myeloid Neoplasms After Allo-SCT
NCT07909733Phase 1Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2027
- Primary completion
- Feb 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imetelstat in myeloid neoplasm, sponsored by University of Wisconsin–Madison. Primary endpoint: Maximum Tolerated Dose at 1 year. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
imetelstat
03
Conditions
myeloid neoplasm
Beyond the preview
Go deeper on NCT07909733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909733.